LJ001

LJ001 is a broad-spectrum and orally active antiviral agent. LJ001 exerts antiviral activities by binding to viral membranes. LJ001 inhibits TGEV and PDCoV infection. LJ001 decreases TGEV N and PDCoV N-protein expression[1][2].

Product Specifications

CAS Number

[851305-26-5]

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

HCV; HIV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/lj001.html

Purity

98.09

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

S=C(N(CC=C)C/1=O)SC1=C/C(O2)=CC=C2C3=CC=CC=C3

Molecular Formula

C17H13NO2S2

Molecular Weight

327.42

Precautions

P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Zhang Y, et al. Rhodanine derivative LJ001 inhibits TGEV and PDCoV replication in vitro. Virus Res. 2020 Nov;289:198167.|[2]Wolf MC, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A. 2010 Feb 16;107 (7) :3157-62.